{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:53:20Z","timestamp":1791579200685,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.breast.2026.104941","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:32:02Z","timestamp":1790688722000},"page":"104941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9821-8144","authenticated-orcid":false,"given":"Alexis","family":"LeVee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saya","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Fisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyne","family":"Face","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Chengappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saliha","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Baclig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Kordic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Huppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Quintal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Melisko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Majure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dame","family":"Idossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Blaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"McCann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.breast.2026.104941_bib1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"10265","key":"10.1016\/j.breast.2026.104941_bib2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.breast.2026.104941_bib3","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Peter","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104941_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2275846","article-title":"Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer","volume":"12","author":"Marhold","year":"2023","journal-title":"OncoImmunology"},{"issue":"0","key":"10.1016\/j.breast.2026.104941_bib5","article-title":"Real-World immune-related adverse events in patients with early triple-negative breast cancer who received pembrolizumab","volume":"0","author":"Jayan","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.breast.2026.104941_bib6","doi-asserted-by":"crossref","unstructured":"Andrade M de O, Gutierres IG, Tavares MC, et al. Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real\/GBECAM 0123 study.Breast. Published online April 10, 2025:104473. doi:10.1016\/j.breast.2025.104473.","DOI":"10.1016\/j.breast.2025.104473"},{"key":"10.1016\/j.breast.2026.104941_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104659","article-title":"105P Immune-related adverse events (irAE) and pathological complete response (pCR) in early TNBC (eTNBC) treated with pembrolizumab (P) plus chemotherapy (CT)","volume":"10","author":"Barberi","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104941_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmorw.2024.100061","article-title":"Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer","volume":"5","author":"Rached","year":"2024","journal-title":"ESMO Real World Data and Digital Oncology"},{"key":"10.1016\/j.breast.2026.104941_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104816","article-title":"262P real-world data on immune-related adverse events with neoadjuvant pembrolizumab in early triple-negative breast cancer at the Norfolk and Norwich University Hospital","volume":"10","author":"Hughes","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.breast.2026.104941_bib10","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1245\/s10434-024-16390-7","article-title":"Real-World outcomes with the KEYNOTE-522 regimen in early-stage triple-negative breast cancer","volume":"32","author":"Connors","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2026.104941_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104601","article-title":"Analysis of risk factors for immune-related adverse events induced by immune checkpoint inhibitor treatment in cancer: a comprehensive systematic review","volume":"207","author":"Jayathilaka","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.breast.2026.104941_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6879","article-title":"Incidence and risk factors of immune-related adverse events induced by immune checkpoint inhibitors among older adults with non-small cell lung cancer","volume":"13","author":"Rong","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104941_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab","volume":"9","author":"Eun","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.breast.2026.104941_bib14","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1007\/s00262-021-02996-3","article-title":"Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis","volume":"70","author":"Suazo-Zepeda","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.breast.2026.104941_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u2014a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1016\/j.breast.2026.104941_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051629","article-title":"Predictive biomarkers for checkpoint inhibitor immune-related adverse events","volume":"15","author":"Les","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.breast.2026.104941_bib17","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1080\/07853890.2021.1931956","article-title":"Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies","volume":"53","author":"Les","year":"2021","journal-title":"Ann Med"},{"issue":"9","key":"10.1016\/j.breast.2026.104941_bib18","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00262-020-02585-w","article-title":"Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors","volume":"69","author":"Peng","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1016\/j.breast.2026.104941_bib19","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.7150\/jca.53242","article-title":"Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study","volume":"12","author":"Egami","year":"2021","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104941_bib20","doi-asserted-by":"crossref","first-page":"9029","DOI":"10.1038\/s41598-021-88307-3","article-title":"Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"11","author":"Michailidou","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.breast.2026.104941_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70214-y","article-title":"Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer","volume":"14","author":"Sugimoto","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.breast.2026.104941_bib22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jjco\/hyy201","article-title":"Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies","volume":"49","author":"Nakamura","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104941_bib23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12957-022-02695-y","article-title":"Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1\/PD-L1 inhibitors: a retrospective analysis","volume":"20","author":"Ma","year":"2022","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.breast.2026.104941_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejca.2021.08.048","article-title":"The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: a prospective study of the French REISAMIC registry","volume":"158","author":"Ruste","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2026.104941_bib25","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.20892\/j.issn.2095-3941.2021.0052","article-title":"Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events","volume":"18","author":"Bai","year":"2021","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.breast.2026.104941_bib26","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2020.08.015","article-title":"Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors","volume":"150","author":"Chu","year":"2020","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.breast.2026.104941_bib27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.31557\/APJCP.2022.23.2.695","article-title":"Identifying early predictive markers for immune-related adverse events in nivolumab-treated patients with renal cell carcinoma and gastric cancer","volume":"23","author":"Takada","year":"2022","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"10.1016\/j.breast.2026.104941_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2022.100603","article-title":"Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy","volume":"32","author":"Caliman","year":"2022","journal-title":"Cancer Treatment and Research Communications"},{"issue":"6_suppl","key":"10.1016\/j.breast.2026.104941_bib29","article-title":"Absolute eosinophil count as predictive biomarker of irAEs in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs)","volume":"39","author":"Giorgione","year":"2021","journal-title":"J Clin Orthod"},{"issue":"3","key":"10.1016\/j.breast.2026.104941_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3390\/immuno1030017","article-title":"Eosinophil count as predictive biomarker of immune-related adverse events (irAEs) in immune checkpoint inhibitors (ICIs) therapies in oncological patients","volume":"1","author":"Giommoni","year":"2021","journal-title":"Immuno"},{"issue":"8","key":"10.1016\/j.breast.2026.104941_bib31","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104941_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/PO-24-00776","article-title":"Immune subtyping identifies patients with hormone receptor\u2013positive early-stage breast cancer who respond to neoadjuvant immunotherapy (IO): results from five IO arms of the I-SPY2 trial","author":"Wolf","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104941_bib33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41591-024-03414-8","article-title":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","volume":"31","author":"Loi","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.breast.2026.104941_bib34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2212 breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.breast.2026.104941_bib35","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.21.02772","article-title":"Atezolizumab with neoadjuvant anti-human epidermal growth factor receptor 2 therapy and chemotherapy in human epidermal growth factor receptor 2-Positive early breast cancer: primary results of the randomized phase III IMpassion050 trial","volume":"40","author":"Huober","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.breast.2026.104941_bib36","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann Oncol"},{"issue":"12_Supplement","key":"10.1016\/j.breast.2026.104941_bib37","doi-asserted-by":"crossref","first-page":"RF3","DOI":"10.1158\/1557-3265.SABCS24-RF3-05","article-title":"Abstract RF3-05: a phase 2 Study of neoadjuvant HER2-targeted therapy +\/- immunotherapy with pembrolizumab (neoHIP)","volume":"31","author":"McArthur","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.breast.2026.104941_bib38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/2326-6066.CIR-19-0986","article-title":"Demographic factors associated with toxicity in patients treated with anti\u2013programmed cell Death-1 therapy","volume":"8","author":"Shah","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.breast.2026.104941_bib39","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejca.2022.12.013","article-title":"Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma","volume":"181","author":"Wong","year":"2023","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.breast.2026.104941_bib40","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor\u2013associated AKI: a multicenter Study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.breast.2026.104941_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.breast.2026.104941_bib42","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/ckj\/sfac109","article-title":"Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study","volume":"15","author":"G\u00e9rard","year":"2022","journal-title":"Clin Kidney J"},{"issue":"12","key":"10.1016\/j.breast.2026.104941_bib43","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.breast.2026.104941_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.breast.2026.104941_bib45","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ckj\/sfad014","article-title":"Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events","volume":"16","author":"Rao Ullur","year":"2023","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1016\/j.breast.2026.104941_bib46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5306\/wjco.v12.i2.103","article-title":"Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses","volume":"12","author":"Peravali","year":"2021","journal-title":"World J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.breast.2026.104941_bib47","article-title":"Impact of ethnicity and immune-related adverse events (IRAE) on outcomes for non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors","volume":"40","author":"Resnick","year":"2022","journal-title":"J Clin Orthod"},{"issue":"8","key":"10.1016\/j.breast.2026.104941_bib48","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/2767-9764.CRC-21-0143","article-title":"Persistent ethnicity-associated disparity in Antitumor effectiveness of immune checkpoint inhibitors despite equal access","volume":"2","author":"Florez","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"5_Supplement","key":"10.1016\/j.breast.2026.104941_bib49","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-GS5-04","article-title":"Abstract GS5-04: identification of symptoms that are associated with irAEs in the I-SPY clinical trial","volume":"83","author":"Basu","year":"2023","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.breast.2026.104941_bib50","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-018-2255-4","article-title":"Opposing roles of eosinophils in cancer","volume":"68","author":"Simon","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"15_suppl","key":"10.1016\/j.breast.2026.104941_bib51","article-title":"A comprehensive meta-analysis of endocrine immune-related adverse events of immune checkpoint inhibitors and outcomes in head and neck cancer and lung cancer","volume":"37","author":"Gomes-Lima","year":"2019","journal-title":"J Clin Orthod"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:38:09Z","timestamp":1791578289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":51,"alternative-id":["S0960977626002511"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104941","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors of immune-related adverse events in patients with early-stage breast cancer: Findings from a multi-institutional retrospective study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104941","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104941"}}